ImmunoGen, Inc. · Waltham, MA United States (NASDAQ: IMGN)
Key ImmunoGen, Inc. Financials
| Company Type | Public -(NASDAQ: IMGN) Headquarters |
|---|---|
| Fiscal Year-End | June |
| 2011 Sales (mil.) | $19.3 |
| 2011 Employees | 248 |
ImmunoGen, Inc. Income Statement
| Jun 11 | Jun 10 | Jun 09 | |
| Revenue | 19.3 | 13.9 | 28.0 |
| Cost of Goods Sold | 0.0 | 0.0 | 0.0 |
| Gross Profit | 19.3 | 13.9 | 28.0 |
| Gross Profit Margin | 100% | 100% | 100% |
| SG&A Expense | 16.0 | 14.9 | 13.9 |
| Depreciation & Amortization | 4.9 | 4.8 | 5.0 |
| Operating Income | (60.2) | (51.2) | (31.8) |
| Operating Margin | -311.8% | -367.5% | -113.7% |
| Nonoperating Income | 1.9 | 0.1 | (0.2) |
| Nonoperating Expenses | -- | -- | -- |
| Income Before Taxes | (58.3) | (51.2) | (32.0) |
| Income Taxes | (0.3) | (0.1) | |
| Net Income After Taxes | (58.3) | (50.9) | (31.9) |
| Continuing Operations | (58.3) | (50.9) | (31.9) |
| Discontinued Operations | -- | -- | -- |
| Total Operations | (58.3) | (50.9) | (31.9) |
| Total Net Income | (58.3) | (50.9) | (31.9) |
| Net Profit Margin | -301.9% | -365.1% | -114.1% |
| Diluted EPS from Total Net Income | (0.85) | (0.87) | (0.63) |
| Dividends per Share | -- | -- | -- |
All amounts in millions of US Dollars except per share amounts.
ImmunoGen, Inc. Balance Sheet
| Assets | Jun 11 | Jun 10 | Jun 09 |
| Current Assets | |||
| Cash | 191.2 | 109.2 | 69.6 |
| Net Receivables | 4.7 | 3.4 | 2.3 |
| Inventories | 0.5 | 1.2 | 1.8 |
| Other Current Assets | 5.2 | 3.3 | 3.1 |
| Total Current Assets | 201.5 | 117.1 | 76.9 |
| Net Fixed Assets | 13.4 | 16.3 | 19.7 |
| Other Noncurrent Assets | 2.7 | 3.8 | 4.2 |
| Total Assets | 217.6 | 137.2 | 100.7 |
| Liabilities | Jun 11 | Jun 10 | Jun 09 |
| Current Liabilities | |||
| Accounts Payable | 3.2 | 3.1 | 1.2 |
| Short-Term Debt | -- | -- | -- |
| Other Current Liabilities | 11.4 | 10.8 | 9.9 |
| Total Current Liabilities | 14.6 | 13.8 | 11.1 |
| Long-Term Debt | -- | -- | -- |
| Other Noncurrent Liabilities | 63.1 | 21.3 | 22.7 |
| Total Liabilities | 77.7 | 35.2 | 33.8 |
| Shareholder's Equity | |||
| Preferred Stock Equity | 0.0 | 0.0 | 0.0 |
| Common Stock Equity | 140.0 | 102.0 | 66.9 |
| Total Equity | 140.0 | 102.0 | 66.9 |
| Shares Outstanding (thou.) | 76,281.0 | 67,931.0 | 56,947.0 |
All amounts in millions of US Dollars except per share amounts.
ImmunoGen, Inc. Cash Flow Statement
| Jun 11 | Jun 10 | Jun 09 | |
| Net Operating Cash Flow | (8) | (41) | (13) |
| Net Investing Cash Flow | (0.7) | (0.9) | 12.0 |
| Net Financing Cash Flow | 90.7 | 81.0 | 39.4 |
| Net Change in Cash | 82.1 | 39.5 | 38.0 |
| Depreciation & Amortization | 4.9 | 4.8 | 5.0 |
| Capital Expenditures | (2.0) | (1.5) | (1.9) |
| Cash Dividends Paid |
All amounts in millions of US Dollars except per share amounts.